3 December 2015 - Eisai Limited announced today that it has received approval from Health Canada for a new indication regarding the use of its anti-epileptic agent Fycimpa (perampanel) as an adjunctive treatment for adults with primary generalized tonic-clonic seizures.

For more details, go to: http://www.newswire.ca/news-releases/eisai-receives-health-canada-approval-for-antiepileptic-agent-fycompa-as-adjunctive-treatment-for-patients-with-primary-generalized-tonic-clonic-seizures-560416311.html